Skip to main content

Advertisement

Table 2 Comparison of the clinical characteristics of patients with different dNLR-PNI grade

From: A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization

Variable dNLR-PNI 0 dNLR-PNI 1 dNLR-PNI 2 P value
(n = 149) (n = 296) (n = 316)
Age (y) 55.8 ± 12.9 54.0 ± 14.0 56.0 ± 13.1 0.15
Gender (male/ female) 131/ 18 252/ 44 259/ 57 0.304
BMI (Kg/m2) 22.9 ± 3.1 22.6 ± 3.3 22.3 ± 2.9 0.271
HBsAg (positive/ negative) 133/ 16 242/ 54 275/ 41 0.061
ALT (IU/L) 57.6 ± 49.9 60.9 ± 64.5 57.9 ± 50.8 0.758
AST (IU/L) 58.1 ± 43.1 72.5 ± 64.4 91.3 ± 76.3 < 0.001b
TBIL (μmol/L) 18.0 ± 13.3 19.3 ± 11.7 24.7 ± 33.6 0.003a
ALB (g/L) 43.1 ± 5.4 40.2 ± 6.1 35.3 ± 4.4 < 0.001b
PT (s) 11.9 ± 1.41 12.4 ± 1.9 12.9 ± 1.6 < 0.001b
INR 1.1 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 0.175
Creatinine (μmol/L) 78.5 ± 15.6 79.9 ± 65.5 73.5 ± 20.4 0.168
Child-pugh grade (A/ B) 145/ 4 257/ 39 220/ 96 < 0.001b
MELD score 5.6 ± 4.3 5.8 ± 5.0 6.3 ± 3.9 0.245
AFP (μg/L), ≤ 400/ > 400 92/ 57 176/ 120 182/ 134 0.69
Largest tumor size (cm) 6.3 ± 3.6 7.4 ± 3.8 9.2 ± 4.7 < 0.001b
Tumor number (single/multiple) 61/ 88 119/ 177 133/ 183 0.93
Vascular invasion (absent/ present) 96/ 53 145/ 151 126/ 190 < 0.001b
TACE treatments (1/ 2/ > 2) 60/ 38/ 51 128/ 76/ 92 165/ 81/ 70 0.026a
  1. dNLR derived neutrophil-to-lymphocyte ratio, PNI prognostic nutritional index, WBC white blood cells, BMI body mass index, ALT alanine transaminase, AST aspartate transaminase, ALB albumin, PT Prothrombin time, INR international normalized ratio, HBsAg hepatitis B surface antigen, AFP α-fetoprotein, TBIl total bilirubin, MELD the model for end stage liver disease
  2. aP < 0.05, when dNLR-PNI 2 vs. dNLR-PNI 0 and dNLR-PNI 1
  3. bP < 0.05 when each group compared with each other